SCHEMBL20180716

SCHEMBL20180716

C/N=C(/Nc1c(OC)cccc1OC)c1ccccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
NPC1 O15118 3/20 0.49
NPSR1 Q6W5P4 1/20 0.44
RAB9A P51151 4/20 0.44
HPGD P15428 2/20 0.42
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
KAT6A Q92794 1/20 0.41
BCL3 P20749 1/20 0.41
PKM P14618 1/20 0.41
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
PYGL P06737 2/20 0.38
GAA P10253 1/20 0.38
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20180830 0.87 NPC1 (0.48) SMN1; SMN2NPC1RAB9AHPGDALDH1A1
SCHEMBL20167669 0.87 NPC1 (0.48) SMN1; SMN2NPC1RAB9AHPGDALDH1A1
SCHEMBL20167556 0.79 SMN1; SMN2 (0.68) SMN1; SMN2NPC1RAB9AHPGDALDH1A1
SCHEMBL21376332 0.79 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AHPGDALDH1A1
SCHEMBL20180831 0.79 NPC1 (0.55) SMN1; SMN2NPC1RAB9AHPGDALDH1A1
SCHEMBL20167853 0.79 HPGD (0.51) SMN1; SMN2NPC1RAB9AHPGDALDH1A1
SCHEMBL18927598 0.69 SMN1; SMN2 (0.41) SMN1; SMN2NPC1RAB9AHPGDALDH1A1
SCHEMBL20207639 0.68 GAA (0.41) SMN1; SMN2NPC1NPSR1RAB9AHPGD
SCHEMBL21222487 0.67 HPGD (0.51) SMN1; SMN2NPC1HPGDALDH1A1KMT2A
SCHEMBL21222482 0.67 KMT2A (0.51) SMN1; SMN2NPC1NPSR1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018093579-A1 TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2018-05-24 WO disclosed